Beyond cardiac troponin: Recent advances in the development of alternative biomarkers for cardiovascular disease
Standard
Beyond cardiac troponin: Recent advances in the development of alternative biomarkers for cardiovascular disease. / Rubini Gimenez, Maria; Twerenbold, Raphael; Mueller, Christian.
In: Expert Review of Molecular Diagnostics, Vol. 15, No. 4, 01.04.2015, p. 547-556.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Beyond cardiac troponin: Recent advances in the development of alternative biomarkers for cardiovascular disease
AU - Rubini Gimenez, Maria
AU - Twerenbold, Raphael
AU - Mueller, Christian
N1 - Publisher Copyright: © 2015 Informa UK, Ltd.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Biomarkers complement clinical assessment, electrocardiogram and cardiac imaging in the diagnosis, risk stratification, triage and management of patients with suspected acute cardiovascular diseases. While there is broad consensus that cardiac troponin is the preferred biomarker in clinical practice for the detection of cardiomyocyte damage, the role of alternative biomarkers is less clear. In fact, despite high quality basic and clinical research by hundreds of groups worldwide, only a single new alternative cardiovascular biomarker (natriuretic peptides) has managed to achieve widespread clinical acceptance and inclusion in contemporary clinical practice guidelines in the last decade. This review aims to discuss the remaining unmet needs (and hence opportunities for new biomarkers) in two major clinical areas: early diagnosis of acute myocardial infarction; and early diagnosis and management of acute heart failure, and to evaluate in detail selected alternative biomarkers and recent insights gained from measuring novel biomarkers in large randomized treatment studies in patients with stable coronary artery disease, a setting in which alternative biomarkers may play a more prominent role in the future.
AB - Biomarkers complement clinical assessment, electrocardiogram and cardiac imaging in the diagnosis, risk stratification, triage and management of patients with suspected acute cardiovascular diseases. While there is broad consensus that cardiac troponin is the preferred biomarker in clinical practice for the detection of cardiomyocyte damage, the role of alternative biomarkers is less clear. In fact, despite high quality basic and clinical research by hundreds of groups worldwide, only a single new alternative cardiovascular biomarker (natriuretic peptides) has managed to achieve widespread clinical acceptance and inclusion in contemporary clinical practice guidelines in the last decade. This review aims to discuss the remaining unmet needs (and hence opportunities for new biomarkers) in two major clinical areas: early diagnosis of acute myocardial infarction; and early diagnosis and management of acute heart failure, and to evaluate in detail selected alternative biomarkers and recent insights gained from measuring novel biomarkers in large randomized treatment studies in patients with stable coronary artery disease, a setting in which alternative biomarkers may play a more prominent role in the future.
KW - acute cardiovascular care
KW - heart failure
KW - myocardial infarction
KW - novel biomarkers
KW - pulmonary embolism
UR - http://www.scopus.com/inward/record.url?scp=84925659149&partnerID=8YFLogxK
U2 - 10.1586/14737159.2015.1010519
DO - 10.1586/14737159.2015.1010519
M3 - SCORING: Review article
C2 - 25676700
AN - SCOPUS:84925659149
VL - 15
SP - 547
EP - 556
JO - EXPERT REV MOL DIAGN
JF - EXPERT REV MOL DIAGN
SN - 1473-7159
IS - 4
ER -
